12. ICU-Acquired Weakness — Diagnostic Criteria and Electrophysiology

Quick Recap

Cross-cutting protocol — companion to Early Mobilization & Rehabilitation and Post-Intensive Care Syndrome (PICS) & Long-Term Follow-Up protocols, both of which reference ICU-acquired weakness as a target for prevention and a driver of long-term physical PICS impairment without detailing the diagnostic entity itself. This protocol addresses the specific diagnostic criteria, the CIP-vs-CIM distinction, and a validated bedside screening tool designed for exactly the population in whom the standard diagnostic approach fails: patients too encephalopathic or uncooperative to voluntarily perform a strength exam.

1. Definition

ICU-acquired weakness (ICUAW): a clinical diagnosis of generalized, symmetric, flaccid muscle weakness developing during critical illness, with no plausible etiology other than the critical illness itself — deliberately defined as a broad, purely clinical (not etiology-specific) diagnosis to allow it to be "applied more generously" across the ICU population, distinguishing it from the more etiologically specific electrophysiological/histological diagnoses of critical illness polyneuropathy (CIP) and critical illness myopathy (CIM) that may underlie it.

MRC (Medical Research Council) sum score: the standard clinical diagnostic tool — manual muscle strength testing across 12 muscle groups bilaterally (shoulder abduction, elbow flexion, wrist extension, hip flexion, knee extension, ankle dorsiflexion), each graded 0–5, for a maximum total of 60. A sum score <48, confirmed on at least two occasions separated by more than 24 hours, is the standard diagnostic threshold for ICUAW.

Critical illness polyneuropathy (CIP): a primary axonal sensorimotor polyneuropathy, electrophysiologically characterized by reduced compound muscle action potential (CMAP) and sensory nerve action potential (SNAP) amplitudes with preserved conduction velocities — a distinct pathophysiological process from myopathy, though the two frequently coexist.

Critical illness myopathy (CIM): a primary myopathy, electrophysiologically characterized by reduced CMAP amplitude with normal SNAP amplitudes (sensory nerves specifically spared, the key electrophysiological distinguishing feature from CIP), increased CMAP duration, reduced muscle excitability on direct stimulation, and myopathic motor unit potentials on needle EMG.

Why the CIP/CIM distinction matters practically, despite ICUAW's deliberately broad clinical definition: CIP and CIM "differ in pathophysiology, prognosis, recovery, and potential treatment" — meaning that while the purely clinical ICUAW diagnosis is appropriately generous and pragmatic for everyday bedside recognition, it is explicitly acknowledged as unsuitable as an outcome measure for interventional/pharmacological trials, since lumping these etiologically distinct entities together obscures differences that matter for prognosis and research — a genuine, practically important limitation of relying on the clinical diagnosis alone in research or complex prognostic contexts.

2. Pathophysiology

ICUAW develops through overlapping mechanisms including systemic inflammation/sepsis-related microvascular and mitochondrial dysfunction, disuse-related muscle atrophy from immobility, hyperglycemia (cross-reference Glycemic Control in Critical Illness protocol — the historical Leuven-era link between tight glycemic control and reduced ICUAW incidence is part of the broader, complicated legacy of that evidence arc), and corticosteroid or neuromuscular blocking agent exposure (cross-reference Neuromuscular Blockade in ARDS protocol, where the ROSE trial notably did not find increased ICUAW with neuromuscular blockade despite the strong a priori mechanistic concern — a genuinely reassuring, if counterintuitive, finding referenced there and relevant context here).

CIP's mechanism: primary axonal degeneration of both motor and sensory peripheral nerve fibers, thought to be driven substantially by the microvascular and metabolic derangements of sepsis/systemic inflammatory response, explaining CIP's strong association with sepsis specifically.

CIM's mechanism: a more directly muscle-intrinsic process involving myosin loss, muscle membrane inexcitability, and mitochondrial dysfunction — mechanistically linked to corticosteroid exposure and neuromuscular blocking agent use, though (per the ROSE trial finding above) this specific causal link has not been as cleanly confirmed in rigorous RCT data as the older, observational-data-driven teaching would suggest.

3. Immediate Stabilization (ABCDE) — Not Applicable in the Traditional Sense

This protocol addresses a diagnostic framework applied over the course of an ICU stay rather than acute stabilization; the relevant "checklist" is a systematic screening and diagnostic approach:

Checklist:

4. Focused History

• Duration and severity of critical illness, sepsis history specifically (strong CIP association)
• Corticosteroid and neuromuscular blocking agent exposure
• Glycemic control trajectory during the ICU stay (cross-reference Glycemic Control in Critical Illness protocol)
• Duration of immobility and mechanical ventilation (cross-reference Early Mobilization & Rehabilitation protocol)
• Baseline neuromuscular function prior to this critical illness, essential for confirming the "no plausible alternative etiology" requirement of the ICUAW definition

5. Comprehensive System-wise Examination

• Neurological/musculoskeletal: the primary examination target — symmetric, flaccid weakness affecting both proximal and distal muscle groups, with craniofacial muscles typically spared or less affected (a genuinely useful bedside discriminating feature, since many alternative diagnoses in the differential do involve facial/bulbar findings)
• Reflexes: reduced or (rarely) absent deep tendon reflexes
• Sensory testing: often difficult to reliably assess in ICU patients given edema, sedation, or coma, but when testable, sensation is typically preserved in CIM and may show deficits specifically in CIP (axonal sensory involvement) — a genuinely useful, if often practically limited, distinguishing feature
• Muscle bulk: atrophy commonly observed on examination

6. Syndrome Identification — Reframed as Diagnostic Pathway Classification

• Cooperative, awake patient able to follow commands: standard MRC sum score assessment (<48 on ≥2 occasions ≥24h apart) is the appropriate, validated diagnostic approach
• Uncooperative or impaired-consciousness patient unable to voluntarily perform strength testing: this is precisely the population where standard MRC assessment fails, and where the peroneal nerve test (PENT) or equivalent simplified electrophysiological screening has specific, validated utility (Section 11) — a genuinely important, practical diagnostic gap that PENT was specifically designed to address
• Diagnostic uncertainty requiring CIP/CIM distinction for prognostic or research purposes: full nerve conduction studies and needle EMG remain the reference standard, beyond what simplified bedside screening tools can provide

7. Differential Diagnosis — Genuinely Extensive and Clinically Important to Actively Exclude

ICUAW is explicitly a diagnosis of exclusion, and the differential is broad enough that failing to actively consider it risks missing treatable alternative diagnoses:

Must-not-miss (treatable, or with distinct management implications):

• Guillain-Barré syndrome: can present similarly but has distinct treatment implications (IVIG/plasmapheresis) and typically has a different electrophysiological pattern and CSF profile
• Myasthenia gravis / myasthenic crisis: fatigable weakness, often with ocular/bulbar involvement (a discriminating feature, since ICUAW typically spares craniofacial muscles), requiring an entirely different treatment approach
• Spinal cord or brainstem lesion: relevant particularly if weakness is asymmetric or has a clear sensory level, atypical for the symmetric pattern expected in ICUAW
• Myositis/inflammatory myopathy: a distinct, potentially treatable myopathic process

Common, condition-independent considerations:

• Residual effects of sedatives, neuromuscular blocking agents, or other medications — must be distinguished from true ICUAW, particularly in the immediate post-sedation period
• Electrolyte derangements (severe hypophosphatemia, hypokalemia, hypermagnesemia) contributing to weakness independent of, or in addition to, true ICUAW (cross-reference Refeeding Syndrome in Critical Illness protocol for the specific hypophosphatemia-weakness connection discussed there)

Diagnostic approach to the differential: careful history and physical examination can exclude many of these alternative conditions; additional studies (neuroimaging, EMG/NCS, infectious workup, inflammatory serologies, CSF analysis where indicated) and specialist input should be pursued when the clinical picture is atypical (asymmetric weakness, prominent cranial nerve involvement, sensory level, or a history suggesting a pre-existing or independent neuromuscular condition) rather than defaulting to an ICUAW diagnosis by assumption.

8. Severity/Risk Assessment

MRC sum score <48: the standard diagnostic threshold; scores can be further used to track trajectory and severity over the ICU stay and into recovery (cross-reference Post-Intensive Care Syndrome protocol for the longer-term functional trajectory this feeds into).

Handgrip dynamometry: an adjunct, more objective quantitative measure — cutoff values below 7 kg for females and 11 kg for males have been proposed as supportive of significant weakness, offering a faster, less subjective bedside alternative or adjunct to the full 12-muscle-group MRC assessment in some protocols.

Incidence: reported at 25–60% in patients mechanically ventilated for more than 7 days, reflecting genuinely substantial prevalence in this population, consistent with the broader PICS physical-domain burden discussed in the Post-Intensive Care Syndrome protocol.

9. Investigations — The Validated Bedside Screening Tool

Peroneal nerve test (PENT): a simplified electrophysiological screening test measuring the peroneal compound muscle action potential (CMAP) amplitude — specifically designed and validated as a rapid (approximately 10 minutes), practical screening alternative to full nerve conduction studies/EMG, and critically, usable in patients who cannot cooperate with voluntary MRC testing (encephalopathy, coma, deep sedation), directly addressing the population where the standard clinical diagnostic approach is simply not feasible.

• CRIMYNE study (original validation): sensitivity 100%, specificity 67% for CIP/CIM against full nerve conduction study/EMG as the reference standard
• CRIMYNE-2 study (multicenter Italian validation, 9 ICUs, n=121, prospective diagnostic accuracy study): confirmed sensitivity 100% (95% CI 96.1–100.0) and found improved specificity 85.2% (95% CI 66.3–95.8) compared to the original CRIMYNE study — the specificity improvement (67% → 85%) did not reach statistical significance (p=0.08) but represented a genuine, favorable trend with a larger, more methodologically robust confirmatory study
• A subsequent, more recent validation: sensitivity 94% (one false negative in 72 patients examined) with specificity 91% — broadly consistent with, and reinforcing, the CRIMYNE-2 findings
• Practical significance: PENT's consistently 100% or near-100% sensitivity across multiple validation studies means a normal PENT result reliably excludes CIP/CIM, making it well-suited as a rule-out screening test; its good-to-excellent specificity (67–91% across studies) means abnormal results warrant, but do not by themselves definitively confirm, further full electrophysiological evaluation — this is precisely the intended, validated clinical role: a screening test that limits the number of patients requiring full, more resource-intensive needle EMG/NCS to confirm a diagnosis, particularly valuable in non-cooperative ICU patients where no other bedside diagnostic option exists
• Timing note: CMAP reduction is an early electrophysiological event that can precede clinical signs of weakness, with onset observable within 24 hours of previously normal findings, and CMAP changes after direct muscle stimulation may precede clinically apparent ICUAW by several days — raising the possibility of genuinely early detection, before weakness becomes clinically manifest, though this early-detection application remains more established as a research finding than as routine, protocolized clinical practice

Full nerve conduction study/EMG: remains the reference standard for definitively distinguishing CIP from CIM and for research-grade diagnostic precision, though resource-intensive and requiring specialized expertise not universally available at the bedside.

10. Point-of-Care Ultrasound

Muscle ultrasound (quadriceps/rectus femoris thickness, echogenicity) is an emerging, non-invasive adjunct for quantifying muscle mass loss and, in some studies, has been examined alongside single nerve conduction studies for diagnostic accuracy — not yet a fully established, standardized replacement for MRC scoring or electrophysiological testing, but a genuinely active area of ongoing methodological development (cross-reference Early Mobilization & Rehabilitation protocol, which notes muscle ultrasound's research-phase status for tracking muscle mass loss over the ICU stay).

11. Evidence-Based Management

This protocol is primarily diagnostic in focus; prevention and treatment strategies are addressed in dedicated companion protocols rather than duplicated here — cross-reference:

• Early Mobilization & Rehabilitation protocol: the primary evidence-based prevention/mitigation strategy, including the honest treatment of the TEAM trial's more nuanced, non-uniformly-positive findings
• Glycemic Control in Critical Illness protocol: the historical (Leuven-era) association between tight glycemic control and reduced ICUAW incidence, contextualized within that protocol's broader NICE-SUGAR-informed caution against tight targets
• Neuromuscular Blockade in ARDS protocol: the reassuring, counterintuitive finding that neither ACURASYS nor ROSE found significantly increased ICUAW with neuromuscular blocking agent use, despite the strong a priori mechanistic concern
• Post-Intensive Care Syndrome (PICS) & Long-Term Follow-Up protocol: the longer-term functional trajectory, prognostic significance, and (largely disappointing, per that protocol's honest treatment of the evidence) post-discharge rehabilitation/follow-up intervention evidence base

This protocol's specific contribution is ensuring the diagnosis itself is made accurately and, critically, in patients who cannot cooperate with standard bedside strength testing — a diagnostic gap that the broader prevention/mitigation-focused protocols above do not themselves address.

12. Organ Support — Not Applicable

13. Disease-Specific Therapy — Not Applicable

Cross-reference Early Mobilization & Rehabilitation protocol for the primary evidence-based intervention (mobilization); no specific pharmacotherapy is established for ICUAW itself once diagnosed.

14. Consultation Matrix

15. Monitoring Framework

• MRC sum score: serial assessment in cooperative patients, tracking trajectory over the ICU stay
• PENT: repeated screening (e.g., weekly, or from 72 hours post-intubation per some protocols) in non-cooperative patients until either a pathological response is detected or the patient becomes cooperative enough for direct MRC assessment
• Handgrip dynamometry: as a faster adjunct/alternative quantitative tracking tool

16. ICU Bundle Checklist

17. Complications

Cross-reference Post-Intensive Care Syndrome (PICS) & Long-Term Follow-Up protocol for the full downstream complication profile (persistent functional disability, prolonged mechanical ventilation, delayed rehabilitation, association with substantially worse long-term mortality) — ICUAW is itself a major contributor to, rather than a separate complication from, the physical domain of PICS.

Diagnostic complications specifically: missed alternative, treatable diagnoses (Guillain-Barré, myasthenic crisis) if the differential is not actively considered before defaulting to an ICUAW diagnosis by assumption.

18. Escalation & De-escalation — Not Directly Applicable

Cross-reference Early Mobilization & Rehabilitation protocol for the escalation of mobilization intensity as function improves.

19. ICU Discharge Criteria — Not Directly Applicable

Cross-reference Post-Intensive Care Syndrome protocol; ICUAW diagnosis and severity, once established, should inform discharge functional-status documentation and rehabilitation planning communicated at care transitions.

20. Documentation & Medicolegal Checklist

• MRC sum score results and dates documented, including confirmation on ≥2 occasions ≥24h apart
• PENT or full NCS/EMG results documented where used, including CIP/CIM distinction if determined
• Alternative diagnoses considered and excluded, documented, particularly for any atypical examination feature
• Diagnosis communicated clearly at care transitions to inform ongoing rehabilitation and prognosis discussion

21. Key Guidelines

• Diagnostic criteria as detailed in Section 1 reflect current consensus (MRC sum score <48 on ≥2 occasions ≥24h apart, with exclusion of alternative etiologies) — no single, universally mandated guideline body has issued a single definitive diagnostic standard beyond this now widely-adopted clinical framework

22. Landmark Trials / Validation Studies

23. Controversies

• The tension between ICUAW's deliberately broad, pragmatic clinical definition and its explicit unsuitability for research/prognostic precision: the field made a genuine, acknowledged tradeoff in adopting a purely clinical, etiology-agnostic diagnosis ("can be applied more generously") specifically because full electrophysiological/histological workup was "very rarely resorted to" in everyday practice — this pragmatic choice has real costs, since CIP and CIM genuinely differ in prognosis and mechanism, and the umbrella ICUAW diagnosis is explicitly acknowledged as inadequate as an outcome measure for interventional trials; this protocol treats this as an intentional, reasonable clinical compromise rather than a flaw to be corrected, while flagging its limitations for research contexts specifically.
• PENT's specificity, while good, is not perfect, and false positives in the CRIMYNE-2 study specifically arose from isolated peroneal mononeuropathy/multineuropathy rather than true generalized CIP/CIM — meaning an abnormal PENT result in a patient with a plausible alternative, localized nerve injury explanation should prompt consideration of that alternative rather than automatic attribution to generalized ICUAW.
• The early-detection potential of CMAP changes preceding clinical weakness (observable within 24–48 hours of normal findings, or even earlier with direct muscle stimulation techniques) remains a genuinely interesting research finding that has not yet translated into a standardized, protocolized early-intervention pathway — the practical clinical value of detecting subclinical electrophysiological changes before weakness is manifest remains an open question, since no specific intervention has been shown to alter trajectory based on this earlier detection alone.
• Muscle ultrasound's role remains genuinely underdeveloped relative to the electrophysiological tools discussed in this protocol — an active area of methodological development rather than an established, standardized diagnostic component at this time.

24. References

1. Stevens RD, Marshall SA, Cornblath DR, et al. A framework for diagnosing and classifying intensive care unit-acquired weakness. Crit Care Med. 2009;37(10 Suppl):S299-S308.
2. Latronico N, Nattino G, Guarneri B, et al; CRIMYNE-2 Study Investigators. Validation of the peroneal nerve test to diagnose critical illness polyneuropathy and myopathy in the intensive care unit: the multicentre Italian CRIMYNE-2 diagnostic accuracy study. F1000Res. 2014;3:127.
3. Latronico N, Bertolini G, Guarneri B, et al. Simplified electrophysiological evaluation of peripheral nerves in critically ill patients: the Italian multi-centre CRIMYNE study. Crit Care. 2007;11(1):R11.
4. Latronico N, Bolton CF. Critical illness polyneuropathy and myopathy: a major cause of muscle weakness and paralysis. Lancet Neurol. 2011;10(10):931-941.
5. De Jonghe B, Sharshar T, Lefaucheur JP, et al; Groupe de Réflexion et d'Étude des Neuromyopathies en Réanimation. Paresis acquired in the intensive care unit: a prospective multicenter study. JAMA. 2002;288(22):2859-2867.
6. Intensive care unit-acquired weakness: unanswered questions and targets for future research. F1000Res. 2019.
7. Critical illness myopathy: diagnostic approach and resulting therapeutic implications. Curr Treat Options Neurol. 2022.
8. Critical illness weakness, polyneuropathy and myopathy: diagnosis, treatment, and long-term outcomes. J Clin Med. 2023.
9. Diagnostic accuracy of single nerve conduction studies and muscle ultrasound to identify critical illness polyneuromyopathy. Crit Care. 2019.
10. The Washington Manual of Critical Care, 4th ed. 2025 — neuromuscular complications of critical illness chapter.
11. ICU Protocols: A Step-wise Approach, 2nd ed. — relevant comprehensive ICU care content.